All stock Upjohn-Mylan merger brings $12bn debt
Pfizer has agreed to spin off its off-patent drug business Upjohn and merge it with generic drug company Mylan, in an all-share deal that will still see $12bn of debt raised.
Unlock this article.
The content you are trying to view is exclusive to our subscribers.
To unlock this article: